• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Jalyn (dutasteride and tamsulosin) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011 

Summary View



Increased Risk of High-grade Prostate Cancer
  • revisions to the labeling regarding the risk of high-grade prostate cancer and the effect of Jalyn on serum prostate specific antigen (PSA) levels. It also provides updated information regarding male breast cancer and includes 4 year results from the CombAT study (ARI40005).